Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the recipient of a large decrease in short interest in March. As of March 13th, there was short interest totaling 41,648 shares, a decrease of 17.1% from the February 26th total of 50,255 shares. Approximately 2.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 26,424 shares, the days-to-cover ratio is presently 1.6 days.

Xenetic Biosciences Stock Performance

NASDAQ:XBIO opened at $2.72 on Monday. The firm has a market capitalization of $6.23 million, a PE ratio of -1.71 and a beta of 2.26. The stock’s fifty day moving average is $2.50 and its 200 day moving average is $2.86. Xenetic Biosciences has a fifty-two week low of $1.90 and a fifty-two week high of $13.93.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.30. Xenetic Biosciences had a negative net margin of 90.09% and a negative return on equity of 51.27%. The company had revenue of $0.77 million during the quarter, compared to analyst estimates of $0.69 million. Equities analysts forecast that Xenetic Biosciences will post -1.01 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Reduce”.

Hedge Funds Weigh In On Xenetic Biosciences

An institutional investor recently bought a new position in Xenetic Biosciences stock. DRW Securities LLC purchased a new stake in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned about 0.60% of Xenetic Biosciences at the end of the most recent quarter. 15.12% of the stock is currently owned by institutional investors.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.